Active substance
Gatifloxacin
- SFDA 4
- US FDA 8
- Health Canada 2
- US price lines 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TYMER 0.3% EYE DROP | 0.3 % | Eye drops · Ophthalmic use | 1 Dropper Container | SAR 28.35 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| Tymer | 0.5 % | Eye drops, solution · Ophthalmic use | 1 Bottle | SAR 47.25 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| ZYMAXID 0.5% eye drops solution | 0.5 % | Ophthalmic solution · Ophthalmic use | 1 Dropper Container | SAR 28.35 | NCE · Prescription | AbbVie Inc | Valid |
| ZYMAR 0.3% OPHTHALMIC SOLUTION | 0.3 % | Ophthalmic solution · Ophthalmic use | 1 Dropper Container | SAR 28.35 | Generic · Prescription | ALLERGAN PHARMACEUTICALS LTD | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ANTIBIOTIC SURGICAL PROPHYLAXIS; MUCOPURULENT CONJUCTIVITIS - GONOCOCCAL INFECTION OF THE EYE - CHLAMYDIAL CONJUNCTIVITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZYMAXID | 0.5% | solution/drops · ophthalmic | ABBVIE | Prescription | 18 May 2010 |
| GATIFLOXACIN | 0.5% | solution/drops · ophthalmic | SANDOZ | Prescription | 11 Jul 2016 |
| GATIFLOXACIN | 0.5% | solution/drops · ophthalmic | CAPLIN | Prescription | 3 Nov 2021 |
| ZYMAR | 0.3% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution/drops · ophthalmic | ALLERGAN | Discontinued | 28 Mar 2003 |
| GATIFLOXACIN | 0.3% | solution/drops · ophthalmic | APOTEX INC | Discontinued | 19 Aug 2011 |
| GATIFLOXACIN | 0.5% | solution/drops · ophthalmic | LUPIN | Discontinued | 28 Aug 2013 |
| GATIFLOXACIN | 0.5% | solution/drops · ophthalmic | HIKMA PHARMS | Discontinued | 3 Sep 2014 |
| GATIFLOXACIN | 0.5% | solution/drops · ophthalmic | RISING | Discontinued | 8 Jun 2018 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP GATIFLOXACIN | 02533235 | 0.3 % / W/V | SOLUTION · OPHTHALMIC | JAMP PHARMA CORPORATION |
| ZYMAR | 02257270 | 0.3 % / W/V | SOLUTION · OPHTHALMIC | ABBVIE CORPORATION |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | GATIFLOXACIN 0.5% EYE DROPS | $8.8549 | per ML | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Mar 2017 ZYMAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 8 Sep 2016 ZYMAXID — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.